Autologous renal cell cancer vaccines using heat shock protein-peptide complexes

Maryam Aalamian, Ephraim Fuchs, Renu Gupta, Daniel L. Levey

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Investigations into the role of heat shock proteins (HSPs) in immune response have progressed well into a third decade, and indications of their use for the treatment of renal cell carcinoma (RCC) in the adjuvant setting will be revealed in the near future when a randomized phase III clinical trial is completed. Additional ongoing and planned randomized clinical trials will test the efficacy of HSP-based vaccines in more advanced stages of RCC. This review describes the compelling scientific rationale behind testing HSPs in RCC against the backdrop of other immunotherapeutic approaches in this indication.

Original languageEnglish (US)
Pages (from-to)425-433
Number of pages9
JournalUrologic Oncology: Seminars and Original Investigations
Issue number5
StatePublished - Sep 2006


  • Autologous
  • Heat shock protein
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Autologous renal cell cancer vaccines using heat shock protein-peptide complexes'. Together they form a unique fingerprint.

Cite this